Cargando…

Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System

Gout is the most familiar inflammatory arthritis condition caused by the elevation of uric acid in the bloodstream. Febuxostat (FBX) is the latest drug approved by the United States Food and Drug Administration (US FDA) for the treatment of gout and hyperuricemia. FBX is characterized by low solubil...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Amodi, Yasir A., Hosny, Khaled M, Alharbi, Waleed S., Safo, Martin K., El-Say, Khalid M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356236/
https://www.ncbi.nlm.nih.gov/pubmed/32531910
http://dx.doi.org/10.3390/pharmaceutics12060534
_version_ 1783558453870985216
author Al-Amodi, Yasir A.
Hosny, Khaled M
Alharbi, Waleed S.
Safo, Martin K.
El-Say, Khalid M
author_facet Al-Amodi, Yasir A.
Hosny, Khaled M
Alharbi, Waleed S.
Safo, Martin K.
El-Say, Khalid M
author_sort Al-Amodi, Yasir A.
collection PubMed
description Gout is the most familiar inflammatory arthritis condition caused by the elevation of uric acid in the bloodstream. Febuxostat (FBX) is the latest drug approved by the United States Food and Drug Administration (US FDA) for the treatment of gout and hyperuricemia. FBX is characterized by low solubility resulting in poor gastrointestinal bioavailability. This study aimed at improving the oral bioavailability of FBX by its incorporation into self-nanoemulsifying delivery systems (SNEDS) with minimum globule size and maximum stability index. The SNEDS-incorporated FBX was loaded into a carrier substrate with a large surface area and lyophilized with other excipients to produce a fluffy, porous-like structure tablet for the transmucosal delivery of FBX. The solubility of FBX was studied in various oils, surfactants, and cosurfactants. Extreme vertices design was utilized to optimize FBX-SNEDS, and subsequently loaded into lyophilized tablets along with suitable excipients. The percentages of the main tablet excipients were optimized using a Box–Behnken design to develop self-nanoemulsifying lyophilized tablets (SNELTs) with minimum disintegration time and maximum drug release. The pharmacokinetics parameters of the optimized FBX-SNELTs were tested in healthy human volunteers in comparison with the marketed FBX tablets. The results revealed that the optimized FBX-SNELTs increased the maximum plasma concentration (C(max)) and decreased the time to reach C(max) (T(max)) with a large area under the curve (AUC) as a result of the enhanced relative oral bioavailability of 146.4%. The significant enhancement of FBX bioavailability is expected to lead to reduced side effects and frequency of administration during the treatment of gout.
format Online
Article
Text
id pubmed-7356236
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73562362020-07-31 Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System Al-Amodi, Yasir A. Hosny, Khaled M Alharbi, Waleed S. Safo, Martin K. El-Say, Khalid M Pharmaceutics Article Gout is the most familiar inflammatory arthritis condition caused by the elevation of uric acid in the bloodstream. Febuxostat (FBX) is the latest drug approved by the United States Food and Drug Administration (US FDA) for the treatment of gout and hyperuricemia. FBX is characterized by low solubility resulting in poor gastrointestinal bioavailability. This study aimed at improving the oral bioavailability of FBX by its incorporation into self-nanoemulsifying delivery systems (SNEDS) with minimum globule size and maximum stability index. The SNEDS-incorporated FBX was loaded into a carrier substrate with a large surface area and lyophilized with other excipients to produce a fluffy, porous-like structure tablet for the transmucosal delivery of FBX. The solubility of FBX was studied in various oils, surfactants, and cosurfactants. Extreme vertices design was utilized to optimize FBX-SNEDS, and subsequently loaded into lyophilized tablets along with suitable excipients. The percentages of the main tablet excipients were optimized using a Box–Behnken design to develop self-nanoemulsifying lyophilized tablets (SNELTs) with minimum disintegration time and maximum drug release. The pharmacokinetics parameters of the optimized FBX-SNELTs were tested in healthy human volunteers in comparison with the marketed FBX tablets. The results revealed that the optimized FBX-SNELTs increased the maximum plasma concentration (C(max)) and decreased the time to reach C(max) (T(max)) with a large area under the curve (AUC) as a result of the enhanced relative oral bioavailability of 146.4%. The significant enhancement of FBX bioavailability is expected to lead to reduced side effects and frequency of administration during the treatment of gout. MDPI 2020-06-10 /pmc/articles/PMC7356236/ /pubmed/32531910 http://dx.doi.org/10.3390/pharmaceutics12060534 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Al-Amodi, Yasir A.
Hosny, Khaled M
Alharbi, Waleed S.
Safo, Martin K.
El-Say, Khalid M
Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
title Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
title_full Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
title_fullStr Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
title_full_unstemmed Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
title_short Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
title_sort investigating the potential of transmucosal delivery of febuxostat from oral lyophilized tablets loaded with a self-nanoemulsifying delivery system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356236/
https://www.ncbi.nlm.nih.gov/pubmed/32531910
http://dx.doi.org/10.3390/pharmaceutics12060534
work_keys_str_mv AT alamodiyasira investigatingthepotentialoftransmucosaldeliveryoffebuxostatfromorallyophilizedtabletsloadedwithaselfnanoemulsifyingdeliverysystem
AT hosnykhaledm investigatingthepotentialoftransmucosaldeliveryoffebuxostatfromorallyophilizedtabletsloadedwithaselfnanoemulsifyingdeliverysystem
AT alharbiwaleeds investigatingthepotentialoftransmucosaldeliveryoffebuxostatfromorallyophilizedtabletsloadedwithaselfnanoemulsifyingdeliverysystem
AT safomartink investigatingthepotentialoftransmucosaldeliveryoffebuxostatfromorallyophilizedtabletsloadedwithaselfnanoemulsifyingdeliverysystem
AT elsaykhalidm investigatingthepotentialoftransmucosaldeliveryoffebuxostatfromorallyophilizedtabletsloadedwithaselfnanoemulsifyingdeliverysystem